Tag: Alzheimers
-
Why Diagnosing Alzheimer’s Early Is So Important
[ad_1] Alzheimer’s patients now have more options than ever for treating their disease— two drugs are approved to treat the causes of Alzheimer’s, and the U.S. Food and Drug Administration is currently considering approving another, which could be available next year. Many researchers are starting to focus on how to get the most out of…
-
Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report
[ad_1] A neuroscientist whose studies undergird an experimental Alzheimer’s drug was “reckless” in his failure to keep or provide original data, an offense that “amounts to significant research misconduct,” an investigation by his university has concluded. The drug, simufilam, is made by Cassava Sciences, a pharmaceutical company based in Texas, and is in advanced clinical…
-
A heartwarming connection among music, memory and Alzheimer’s : NPR
[ad_1] Adam Kaye and his mother, Marti Kaye, spend every Sunday together. Adam normally plays some of her favorite songs on his guitar, with Marti whistling or humming along. But he recently had shoulder surgery and won’t be able to strum a guitar for a while. Dustin Jones/NPR hide caption toggle caption Dustin Jones/NPR Adam…
-
The real costs of the new Alzheimer’s drug, Leqembi — and why taxpayers will foot much of the bill
[ad_1] The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income seniors most likely to suffer from dementia. Medicare and Medicaid patients will make up 92% of the market for lecanemab,…
-
Donanemab: What we know about new Alzheimer’s drug
[ad_1] Key PointsDonanemab is a new Alzheimer’s drug that has been found to slow the progression of the disease.In the trials, donanemab appears to have slowed the pace of the disease by about a third.It is awaiting approval from a regulator. An experimental new drug could offer hope and delay the severity of some symptoms…
-
Experimental Alzheimer’s drug donanemab outperforms Leqembi in clinical trial : Shots
[ad_1] The image shows amyloid plaques in the brains of three patients in the early stages of Alzheimer’s. Those plaques are greatly reduced in the first two patients, who got donanemab, but remain unchanged in a patient who received no treatment. Eli Lilly and Company hide caption toggle caption Eli Lilly and Company The image…
-
Leqembi, A New Alzheimer’s Treatment, Will Soon Be Available
[ad_1] Alzheimer’s is a heartbreaking medical condition that affects millions of people and families. It can cause debilitating issues like memory loss, confusion and personality changes. According to the Centers for Disease Control and Prevention, roughly 5.8 million Americans are living with the disease as of 2020, making it the most prevalent form of dementia.…
-
New study links gum disease to buildup of Alzheimer’s plaque formation
[ad_1] Scientists have found a link between periodontal (gum) disease and the formation of amyloid plaque, a hallmark of Alzheimer’s disease. The study, published in the Journal of Neuroinflammation, found that gum disease can lead to changes in brain cells called microglial cells, responsible for defending the brain from amyloid plaque, a type of protein…
-
Alzheimer’s drug; Ukraine cluster bombs; tap water chemicals : NPR
[ad_1] Good morning. You’re reading the Up First newsletter. Subscribe here to get it delivered to your inbox, and listen to the Up First podcast for all the news you need to start your day. Today’s top stories The Biden administration is expected to announce today that it will send cluster munitions to Ukraine, despite…
-
The First Fully Approved Alzheimer’s Drug Won’t Be Easy To Get
[ad_1] It’s a decision that millions of people affected by Alzheimer’s disease and their families have been waiting for—the first fully approved drug that treats the disease, rather than its symptoms. On July 6, the U.S. Food and Drug Administration (FDA) granted full approval for lecanemab, or Leqembi, to treat Alzheimer’s in people in the…